Latest Pharma Insights
Over The Counter: Making The Case For Switch, With AESGP’s Christelle Anquez-Traxler
HBW Insight speaks to AESGP's Christelle Anquez-Traxler ahead of the association's first Switch Day conference in Brussels, on why prescription-to-non-prescription switch remains one of the most undervalued forms of innovation in self-care.
HBW Insight - September 1, 2026
HBW Insight speaks to AESGP's Christelle Anquez-Traxler ahead of the association's first Switch Day conference in Brussels, on why prescription-to-non-prescription switch remains one of the most undervalued forms of innovation in self-care.
HBW Insight - September 1, 2026
Two Platforms, One Playbook: Medtronic Pays For Reach In Robotics And Structural Heart
Medtronic has found a way to compete in surgical robotics and structural heart without making an all-or-nothing bet in either — two deals announced this quarter that look different on the surface but are built on the same logic: minimum commitment now, maximum optionality later.
Medtech Insight - September 1, 2026
Medtronic has found a way to compete in surgical robotics and structural heart without making an all-or-nothing bet in either — two deals announced this quarter that look different on the surface but are built on the same logic: minimum commitment now, maximum optionality later.
Medtech Insight - September 1, 2026
Success For AstraZeneca And Hutchmed’s Oral Combo In First Line NSCLC
Positive topline results from the China-only SANOVO study in first-line patients help underpin Tagrisso’s dominance in EGFR-mutated lung cancer treatment
Scrip - September 1, 2026
Positive topline results from the China-only SANOVO study in first-line patients help underpin Tagrisso’s dominance in EGFR-mutated lung cancer treatment
Scrip - September 1, 2026
Aurobindo’s Lannett Makes Respiratory Debut With Advair Rival
Aurobindo has confirmed that its Lannett subsidiary has launched its US generic rival to Advair. But almost seven years since Lannett first struck a development deal with Respirent for the complex generic, the competitive landscape now looks very different.
Generics Bulletin - September 1, 2026
Aurobindo has confirmed that its Lannett subsidiary has launched its US generic rival to Advair. But almost seven years since Lannett first struck a development deal with Respirent for the complex generic, the competitive landscape now looks very different.
Generics Bulletin - September 1, 2026
Novartis’s Remibrutinib Scores Phase III MS Win As BTK Race Intensifies
The drug’s next test will be whether full data can translate a headline Phase III win into a meaningful position in the crowded BTK market where liver safety will be crucial.
Scrip - September 1, 2026
The drug’s next test will be whether full data can translate a headline Phase III win into a meaningful position in the crowded BTK market where liver safety will be crucial.
Scrip - September 1, 2026
ESC 2026: Guidelines Raise Abbott’s HeartMate 3 To Class I, Widen Device Openings Across Cardiology
The congress reset where cardiac devices sit in guidelines: Abbott's HeartMate 3 rose to Class I and CardioMEMS to IIa; J&J's Impella won its own category but not the Class I that triggers its Abiomed payout; and new rehab and CVD-CKD frameworks opened lanes for digital health and diagnostics.
Medtech Insight - September 1, 2026
The congress reset where cardiac devices sit in guidelines: Abbott's HeartMate 3 rose to Class I and CardioMEMS to IIa; J&J's Impella won its own category but not the Class I that triggers its Abiomed payout; and new rehab and CVD-CKD frameworks opened lanes for digital health and diagnostics.
Medtech Insight - September 1, 2026
Scrip’s Guide To September 2026: Conferences Are Back And Novel Approvals Beckon
September will see a busier medical meeting schedule with upcoming conferences including the ERS respiratory meeting, and brisk approval activity at the US FDA. Decisions are expected for novel products for Parkinson’s and a host of rare diseases.
Scrip - September 1, 2026
September will see a busier medical meeting schedule with upcoming conferences including the ERS respiratory meeting, and brisk approval activity at the US FDA. Decisions are expected for novel products for Parkinson’s and a host of rare diseases.
Scrip - September 1, 2026
Autoimmune CAR-T Double Blow As Novartis And BMS Pause Trials On Safety Concerns
Three deaths from a rare immune toxicity stopped Novartis’s trials while BMS paused its own after “transient and reversible inflammatory events.”
Scrip - September 1, 2026
Three deaths from a rare immune toxicity stopped Novartis’s trials while BMS paused its own after “transient and reversible inflammatory events.”
Scrip - September 1, 2026
Sun’s US MFN Move: Risk Mitigation And A Pricing Tightrope
Sun Pharma joins US MFN pricing pact, buying time on tariffs and betting on policy clarity as innovative medicines reshape its growth story. The firm’s global pricing architecture may have just turned a bit more sensitive, experts say.
Scrip - September 1, 2026
Sun Pharma joins US MFN pricing pact, buying time on tariffs and betting on policy clarity as innovative medicines reshape its growth story. The firm’s global pricing architecture may have just turned a bit more sensitive, experts say.
Scrip - September 1, 2026
Alvotech Delivers On Promise Of Subcutaneous Vedolizumab Filing
The FDA’s acceptance of Alvotech’s AVT80 application expands its US Entyvio biosimilar program into subcutaneous presentations, as the firm positions for first-wave competition alongside intravenous candidate AVT16.
Generics Bulletin - September 1, 2026
The FDA’s acceptance of Alvotech’s AVT80 application expands its US Entyvio biosimilar program into subcutaneous presentations, as the firm positions for first-wave competition alongside intravenous candidate AVT16.
Generics Bulletin - September 1, 2026
Merck India Chief On Building A Rare Disease Franchise From The Ground Up
As Merck prepares to foray into rare diseases in India, Pratima Reddy, managing director of Merck Specialities, is studying the landscape and assessing capabilities needed to launch Ogsiveo and Gomekli, she tells Scrip in this interview.
Scrip - September 1, 2026
As Merck prepares to foray into rare diseases in India, Pratima Reddy, managing director of Merck Specialities, is studying the landscape and assessing capabilities needed to launch Ogsiveo and Gomekli, she tells Scrip in this interview.
Scrip - September 1, 2026
Strategic Intent: Beyond The Breakthrough - From Approval To Adoption
A medical device can work beautifully and still go nowhere. The conversation digs into medtech’s hardest problem — not inventing a technology, but getting physicians to switch and payers to cover it.
In Vivo - September 1, 2026
A medical device can work beautifully and still go nowhere. The conversation digs into medtech’s hardest problem — not inventing a technology, but getting physicians to switch and payers to cover it.
In Vivo - September 1, 2026
Samsung Bioepis Makes A Start On Biosimilar Taltz Trials
Samsung Bioepis has announced the start of a Phase I trial for its SB35 biosimilar rival to Eli Lilly’s Taltz. But it is not the only developer eyeing the ixekizumab opportunity.
Generics Bulletin - September 1, 2026
Samsung Bioepis has announced the start of a Phase I trial for its SB35 biosimilar rival to Eli Lilly’s Taltz. But it is not the only developer eyeing the ixekizumab opportunity.
Generics Bulletin - September 1, 2026
Advancing CNS Drug Development Through AI, New Approach Methodologies and Regulatory Innovation
Hear how emerging technologies and evolving regulatory thinking are helping sponsors navigate the complexities of neuroscience drug development.
Scrip - September 1, 2026
Hear how emerging technologies and evolving regulatory thinking are helping sponsors navigate the complexities of neuroscience drug development.
Scrip - September 1, 2026
PharmaPath’s Strategy for Sustainable Global Growth
CEO Eirini Vasilopoulos shares insights on scaling across global markets while maintaining a commitment to quality, transparency, and long-term partnership success.
Generics Bulletin - September 1, 2026
CEO Eirini Vasilopoulos shares insights on scaling across global markets while maintaining a commitment to quality, transparency, and long-term partnership success.
Generics Bulletin - September 1, 2026
mRNA’s Next Act: Beyond Cancer And Vaccines
Moderna's melanoma data have strengthened the case for mRNA in cancer, but developers are now testing how far the technology can extend across rare diseases, respiratory medicine and cell therapy.
In Vivo - September 1, 2026
Moderna's melanoma data have strengthened the case for mRNA in cancer, but developers are now testing how far the technology can extend across rare diseases, respiratory medicine and cell therapy.
In Vivo - September 1, 2026
Longest Acting Lp(a) Inhibitor? SBP’s Kylo-11 May Reach A Year
Final results from a Phase I study of Sino Biopharmaceutical’s Kylo-11, a lipoprotein(a) siRNA candidate, showed up to 97.0% reduction of Lp(a) levels from baseline in healthy participants at 48 weeks.
Scrip - September 1, 2026
Final results from a Phase I study of Sino Biopharmaceutical’s Kylo-11, a lipoprotein(a) siRNA candidate, showed up to 97.0% reduction of Lp(a) levels from baseline in healthy participants at 48 weeks.
Scrip - September 1, 2026
Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - September 1, 2026
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - September 1, 2026
Civica Portfolio Grows By Three And Prices Fall Up To 98%
Civica, the US non-profit dedicated to bringing low cost and accessible generics has now added three more products to its growing portfolio, “priced up to 98% lower than average for other generic versions.”
Generics Bulletin - September 1, 2026
Civica, the US non-profit dedicated to bringing low cost and accessible generics has now added three more products to its growing portfolio, “priced up to 98% lower than average for other generic versions.”
Generics Bulletin - September 1, 2026
Who’s Hired? Reddy’s Veteran Sapra Takes Top Job At Gland
In our regular column, Generics Bulletin rounds up the most significant recent appointments across the generics and biosimilars industry.
Generics Bulletin - September 1, 2026
In our regular column, Generics Bulletin rounds up the most significant recent appointments across the generics and biosimilars industry.
Generics Bulletin - September 1, 2026
What’s Next? Five Things To Look Out For In September
Generics Bulletin previews the most noteworthy and anticipated events for September 2026.
Generics Bulletin - September 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for September 2026.
Generics Bulletin - September 1, 2026
On Your Radar? What To Look Out For In September
Featuring a full calendar of events and important deadlines in September, HBW Insight's 'On Your Radar?' highlights key dates for your diary across both consumer health and cosmetics.
HBW Insight - September 1, 2026
Featuring a full calendar of events and important deadlines in September, HBW Insight's 'On Your Radar?' highlights key dates for your diary across both consumer health and cosmetics.
HBW Insight - September 1, 2026
FDA Sets Sights On Vraylar And Lynparza With Latest PSGs
The FDA’s latest batch of product-specific guidances for generic development includes advice for developers of rivals to Vraylar, Lynparza, Vyvanse and Olumiant, among other products covered by the 55 new and revised PSGs.
Generics Bulletin - September 1, 2026
The FDA’s latest batch of product-specific guidances for generic development includes advice for developers of rivals to Vraylar, Lynparza, Vyvanse and Olumiant, among other products covered by the 55 new and revised PSGs.
Generics Bulletin - September 1, 2026
GSK And Other Firms Look To Follow Moderna Into mRNA Flu Vaccine Space
Recent FDA nod for mFLUSIVA may have opened the door for other novel flu vaccine approaches. GSK is moving into Phase III, while Osivax and GC announced a T-cell program, one of an estimated 46 next-gen flu vaccine candidates advancing in the clinic.
Scrip - September 1, 2026
Recent FDA nod for mFLUSIVA may have opened the door for other novel flu vaccine approaches. GSK is moving into Phase III, while Osivax and GC announced a T-cell program, one of an estimated 46 next-gen flu vaccine candidates advancing in the clinic.
Scrip - September 1, 2026
Trump Administration Signs Nine New MFN Deals, The First With Mid-Sized Firms
The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according to the White House, and agreements with companies representing the remainder are expected “very soon.”
Scrip - September 1, 2026
The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according to the White House, and agreements with companies representing the remainder are expected “very soon.”
Scrip - September 1, 2026
Success For AstraZeneca And Hutchmed’s Oral Combo In First Line NSCLC
Positive topline results from the China-only SANOVO study in first-line patients help underpin Tagrisso’s dominance in EGFR-mutated lung cancer treatment
Scrip - September 1, 2026
Positive topline results from the China-only SANOVO study in first-line patients help underpin Tagrisso’s dominance in EGFR-mutated lung cancer treatment
Scrip - September 1, 2026
Novartis’s Remibrutinib Scores Phase III MS Win As BTK Race Intensifies
The drug’s next test will be whether full data can translate a headline Phase III win into a meaningful position in the crowded BTK market where liver safety will be crucial.
Scrip - September 1, 2026
The drug’s next test will be whether full data can translate a headline Phase III win into a meaningful position in the crowded BTK market where liver safety will be crucial.
Scrip - September 1, 2026
Scrip’s Guide To September 2026: Conferences Are Back And Novel Approvals Beckon
September will see a busier medical meeting schedule with upcoming conferences including the ERS respiratory meeting, and brisk approval activity at the US FDA. Decisions are expected for novel products for Parkinson’s and a host of rare diseases.
Scrip - September 1, 2026
September will see a busier medical meeting schedule with upcoming conferences including the ERS respiratory meeting, and brisk approval activity at the US FDA. Decisions are expected for novel products for Parkinson’s and a host of rare diseases.
Scrip - September 1, 2026
Autoimmune CAR-T Double Blow As Novartis And BMS Pause Trials On Safety Concerns
Three deaths from a rare immune toxicity stopped Novartis’s trials while BMS paused its own after “transient and reversible inflammatory events.”
Scrip - September 1, 2026
Three deaths from a rare immune toxicity stopped Novartis’s trials while BMS paused its own after “transient and reversible inflammatory events.”
Scrip - September 1, 2026
Sun’s US MFN Move: Risk Mitigation And A Pricing Tightrope
Sun Pharma joins US MFN pricing pact, buying time on tariffs and betting on policy clarity as innovative medicines reshape its growth story. The firm’s global pricing architecture may have just turned a bit more sensitive, experts say.
Scrip - September 1, 2026
Sun Pharma joins US MFN pricing pact, buying time on tariffs and betting on policy clarity as innovative medicines reshape its growth story. The firm’s global pricing architecture may have just turned a bit more sensitive, experts say.
Scrip - September 1, 2026
Merck India Chief On Building A Rare Disease Franchise From The Ground Up
As Merck prepares to foray into rare diseases in India, Pratima Reddy, managing director of Merck Specialities, is studying the landscape and assessing capabilities needed to launch Ogsiveo and Gomekli, she tells Scrip in this interview.
Scrip - September 1, 2026
As Merck prepares to foray into rare diseases in India, Pratima Reddy, managing director of Merck Specialities, is studying the landscape and assessing capabilities needed to launch Ogsiveo and Gomekli, she tells Scrip in this interview.
Scrip - September 1, 2026
Advancing CNS Drug Development Through AI, New Approach Methodologies and Regulatory Innovation
Hear how emerging technologies and evolving regulatory thinking are helping sponsors navigate the complexities of neuroscience drug development.
Scrip - September 1, 2026
Hear how emerging technologies and evolving regulatory thinking are helping sponsors navigate the complexities of neuroscience drug development.
Scrip - September 1, 2026
Longest Acting Lp(a) Inhibitor? SBP’s Kylo-11 May Reach A Year
Final results from a Phase I study of Sino Biopharmaceutical’s Kylo-11, a lipoprotein(a) siRNA candidate, showed up to 97.0% reduction of Lp(a) levels from baseline in healthy participants at 48 weeks.
Scrip - September 1, 2026
Final results from a Phase I study of Sino Biopharmaceutical’s Kylo-11, a lipoprotein(a) siRNA candidate, showed up to 97.0% reduction of Lp(a) levels from baseline in healthy participants at 48 weeks.
Scrip - September 1, 2026
Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - September 1, 2026
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - September 1, 2026
GSK And Other Firms Look To Follow Moderna Into mRNA Flu Vaccine Space
Recent FDA nod for mFLUSIVA may have opened the door for other novel flu vaccine approaches. GSK is moving into Phase III, while Osivax and GC announced a T-cell program, one of an estimated 46 next-gen flu vaccine candidates advancing in the clinic.
Scrip - September 1, 2026
Recent FDA nod for mFLUSIVA may have opened the door for other novel flu vaccine approaches. GSK is moving into Phase III, while Osivax and GC announced a T-cell program, one of an estimated 46 next-gen flu vaccine candidates advancing in the clinic.
Scrip - September 1, 2026
Trump Administration Signs Nine New MFN Deals, The First With Mid-Sized Firms
The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according to the White House, and agreements with companies representing the remainder are expected “very soon.”
Scrip - September 1, 2026
The deals with nine companies mean the MFN policy's reach now covers 89% of the branded US pharmaceutical market, according to the White House, and agreements with companies representing the remainder are expected “very soon.”
Scrip - September 1, 2026
Two Platforms, One Playbook: Medtronic Pays For Reach In Robotics And Structural Heart
Medtronic has found a way to compete in surgical robotics and structural heart without making an all-or-nothing bet in either — two deals announced this quarter that look different on the surface but are built on the same logic: minimum commitment now, maximum optionality later.
Medtech Insight - September 1, 2026
Medtronic has found a way to compete in surgical robotics and structural heart without making an all-or-nothing bet in either — two deals announced this quarter that look different on the surface but are built on the same logic: minimum commitment now, maximum optionality later.
Medtech Insight - September 1, 2026
ESC 2026: Guidelines Raise Abbott’s HeartMate 3 To Class I, Widen Device Openings Across Cardiology
The congress reset where cardiac devices sit in guidelines: Abbott's HeartMate 3 rose to Class I and CardioMEMS to IIa; J&J's Impella won its own category but not the Class I that triggers its Abiomed payout; and new rehab and CVD-CKD frameworks opened lanes for digital health and diagnostics.
Medtech Insight - September 1, 2026
The congress reset where cardiac devices sit in guidelines: Abbott's HeartMate 3 rose to Class I and CardioMEMS to IIa; J&J's Impella won its own category but not the Class I that triggers its Abiomed payout; and new rehab and CVD-CKD frameworks opened lanes for digital health and diagnostics.
Medtech Insight - September 1, 2026
Over The Counter: Making The Case For Switch, With AESGP’s Christelle Anquez-Traxler
HBW Insight speaks to AESGP's Christelle Anquez-Traxler ahead of the association's first Switch Day conference in Brussels, on why prescription-to-non-prescription switch remains one of the most undervalued forms of innovation in self-care.
HBW Insight - September 1, 2026
HBW Insight speaks to AESGP's Christelle Anquez-Traxler ahead of the association's first Switch Day conference in Brussels, on why prescription-to-non-prescription switch remains one of the most undervalued forms of innovation in self-care.
HBW Insight - September 1, 2026
On Your Radar? What To Look Out For In September
Featuring a full calendar of events and important deadlines in September, HBW Insight's 'On Your Radar?' highlights key dates for your diary across both consumer health and cosmetics.
HBW Insight - September 1, 2026
Featuring a full calendar of events and important deadlines in September, HBW Insight's 'On Your Radar?' highlights key dates for your diary across both consumer health and cosmetics.
HBW Insight - September 1, 2026
Aurobindo’s Lannett Makes Respiratory Debut With Advair Rival
Aurobindo has confirmed that its Lannett subsidiary has launched its US generic rival to Advair. But almost seven years since Lannett first struck a development deal with Respirent for the complex generic, the competitive landscape now looks very different.
Generics Bulletin - September 1, 2026
Aurobindo has confirmed that its Lannett subsidiary has launched its US generic rival to Advair. But almost seven years since Lannett first struck a development deal with Respirent for the complex generic, the competitive landscape now looks very different.
Generics Bulletin - September 1, 2026
Alvotech Delivers On Promise Of Subcutaneous Vedolizumab Filing
The FDA’s acceptance of Alvotech’s AVT80 application expands its US Entyvio biosimilar program into subcutaneous presentations, as the firm positions for first-wave competition alongside intravenous candidate AVT16.
Generics Bulletin - September 1, 2026
The FDA’s acceptance of Alvotech’s AVT80 application expands its US Entyvio biosimilar program into subcutaneous presentations, as the firm positions for first-wave competition alongside intravenous candidate AVT16.
Generics Bulletin - September 1, 2026
Samsung Bioepis Makes A Start On Biosimilar Taltz Trials
Samsung Bioepis has announced the start of a Phase I trial for its SB35 biosimilar rival to Eli Lilly’s Taltz. But it is not the only developer eyeing the ixekizumab opportunity.
Generics Bulletin - September 1, 2026
Samsung Bioepis has announced the start of a Phase I trial for its SB35 biosimilar rival to Eli Lilly’s Taltz. But it is not the only developer eyeing the ixekizumab opportunity.
Generics Bulletin - September 1, 2026
PharmaPath’s Strategy for Sustainable Global Growth
CEO Eirini Vasilopoulos shares insights on scaling across global markets while maintaining a commitment to quality, transparency, and long-term partnership success.
Generics Bulletin - September 1, 2026
CEO Eirini Vasilopoulos shares insights on scaling across global markets while maintaining a commitment to quality, transparency, and long-term partnership success.
Generics Bulletin - September 1, 2026
Civica Portfolio Grows By Three And Prices Fall Up To 98%
Civica, the US non-profit dedicated to bringing low cost and accessible generics has now added three more products to its growing portfolio, “priced up to 98% lower than average for other generic versions.”
Generics Bulletin - September 1, 2026
Civica, the US non-profit dedicated to bringing low cost and accessible generics has now added three more products to its growing portfolio, “priced up to 98% lower than average for other generic versions.”
Generics Bulletin - September 1, 2026
Who’s Hired? Reddy’s Veteran Sapra Takes Top Job At Gland
In our regular column, Generics Bulletin rounds up the most significant recent appointments across the generics and biosimilars industry.
Generics Bulletin - September 1, 2026
In our regular column, Generics Bulletin rounds up the most significant recent appointments across the generics and biosimilars industry.
Generics Bulletin - September 1, 2026
What’s Next? Five Things To Look Out For In September
Generics Bulletin previews the most noteworthy and anticipated events for September 2026.
Generics Bulletin - September 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for September 2026.
Generics Bulletin - September 1, 2026
FDA Sets Sights On Vraylar And Lynparza With Latest PSGs
The FDA’s latest batch of product-specific guidances for generic development includes advice for developers of rivals to Vraylar, Lynparza, Vyvanse and Olumiant, among other products covered by the 55 new and revised PSGs.
Generics Bulletin - September 1, 2026
The FDA’s latest batch of product-specific guidances for generic development includes advice for developers of rivals to Vraylar, Lynparza, Vyvanse and Olumiant, among other products covered by the 55 new and revised PSGs.
Generics Bulletin - September 1, 2026
Strategic Intent: Beyond The Breakthrough - From Approval To Adoption
A medical device can work beautifully and still go nowhere. The conversation digs into medtech’s hardest problem — not inventing a technology, but getting physicians to switch and payers to cover it.
In Vivo - September 1, 2026
A medical device can work beautifully and still go nowhere. The conversation digs into medtech’s hardest problem — not inventing a technology, but getting physicians to switch and payers to cover it.
In Vivo - September 1, 2026
mRNA’s Next Act: Beyond Cancer And Vaccines
Moderna's melanoma data have strengthened the case for mRNA in cancer, but developers are now testing how far the technology can extend across rare diseases, respiratory medicine and cell therapy.
In Vivo - September 1, 2026
Moderna's melanoma data have strengthened the case for mRNA in cancer, but developers are now testing how far the technology can extend across rare diseases, respiratory medicine and cell therapy.
In Vivo - September 1, 2026